Introduction: The protective and/or therapeutic potential of tadalafil (TDL) on cyclophosphamide (CP)-induced hemorrhagic cystitis (HC) and testicular dysfunction in rats was evaluated. Materials and Methods: The animals except from the control group were divided into four groups and treated with saline, or 1, 5 or 10 mg/kg TDL orally (CP, TDL1, TDL5 and TDL10 groups, respectively) before and after CP injection. Body and organ weights, sperm count, cGMP, nitric oxide (NO), IL-6 and IL-10 levels in serum and bladder tissue, and serum testosterone (T), LH and FSH levels were determined. The histological analysis of bladder and testis was performed and the number of apoptotic cells was determined. Results and Conclusion: The CP group had decreased cGMP and NO levels in the bladder, serum T level (p < 0.05) and sperm count (p < 0.001) and higher IL-6 levels in serum and bladder (p < 0.01). Treatment with TDL resulted in increased cGMP (p < 0.001), NO (p < 0.05) and serum T (p < 0.05) levels. Histological analysis of the CP group showed severe HC in bladder and testicular damage. TDL-treated animals showed a dose-dependent improvement in all of these histological impairments. In conclusion, a selective inhibitor of phosphodiesterase-5 enzyme, TDL, showed a protective and/or therapeutic effect on CP-induced HC and testicular dysfunction in rats.

Keywords:
Cyclophosphamide, Tadalafil, Rat, Hemorrhagic cystitis, Testicular dysfunction
1.
Bennett AH: Cyclophosphamide and haemorrhagic cystitis. J Urol 1974;111:603-606.
2.
Gray KJ, Engelmann UH, Johnson EH, Fishman IJ: Evaluation of misoprostol cytoprotection of the bladder with cyclophosphamide (Cytoxan) therapy. J Urol 1986;136:497-500.
3.
Brock N, Pohl J, Stekar J: Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. I. Experimental studies on the urotoxicity of alkylating compounds. Eur J Cancer 1981;17:595-607.
4.
Koss LG: A light and electron microscopic study of the effects of a single dose of cyclophosphamide on various organs in the rat. I. The urinary bladder. Lab Invest 1967;16:44-65.
5.
Bischel MD: Cyclophosphamide-hemorrhagic cystitis following prolonged low-dose therapy. JAMA 1979;242:238-239.
6.
Mukhtar S, Woodhouse C: The management of cyclophosphamide-induced haematuria. BJU Int 2010;105:908-912.
7.
Shepherd JD, Pringle LE, Barnett MJ, Klingemann HG, Reece DE, Phillips GL: Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation. J Clin Oncol 1991;9:2016-2020.
8.
Howell S, Shalet S: Gonadal damage from chemotherapy and radiotherapy. Endocrinol Metab Clin North Am 1998;27:927-943.
9.
Fraiser LH, Kanekal S, Kehrer JP: Cyclophosphamide toxicity. Characterising and avoiding the problem. Drugs 1991;42:781-795.
10.
Motawi TM, Sadik NA, Refaat A: Cytoprotective effects of D,L-α-lipoic acid or squalene on cyclophosphamide-induced oxidative injury: an experimental study on rat myocardium, testicles and urinary bladder. Food Chem Toxicol 2010;48:2326-2336.
11.
Anderson D, Bishop JB, Garner RC, Ostrosky-Wegman P, Selby PB: Cyclophosphamide: review of its mutagenicity for an assessment of potential germ cell risks. Mutat Res 1995;330:115-181.
12.
Kaur F, Sangha GK, Bilaspuri GS: Cyclophosphamide-induced structural and biochemical changes in testis and epididymidis of rats. Indian J Exp Biol 1997;35:771-775.
13.
Das UB, Mallick M, Debnath JM, Ghosh D: Protective effect of ascorbic acid on cyclophosphamide-induced testicular gametogenic and androgenic disorders in male rats. Asian J Androl 2002;4:201-207.
14.
Manda K, Bhatia AL: Prophylactic action of melatonin against cyclophosphamide-induced oxidative stress in mice. Cell Biol Toxicol 2003;19:367-372.
15.
Türk G, Ceribaşi AO, Sakin F, Sönmez M, Ateşşahin A: Antiperoxidative and anti-apoptotic effects of lycopene and ellagic acid on cyclophosphamide-induced testicular lipid peroxidation and apoptosis. Reprod Fertil Dev 2010;22:587-596.
16.
Drumond AL, Weng CC, Wang G, Chiarini-Garcia H, Eras-Garcia L, Meistrich ML: Effects of multiple doses of cyclophosphamide on mouse testes: accessing the germ cells lost, and the functional damage of stem cells. Reprod Toxicol 2011;32:395-406.
17.
Rotella DP: Phosphodiesterase-5 inhibitors: current status and potential applications. Nat Rev Drug Discov 2002;1:674-682.
18.
Wang T, Liu Y, Chen L, Wang X, Hu XR, Feng YL, Liu DS, Xu D, Duan YP, Lin J, Ou XM, Wen FQ: Effect of sildenafil on acrolein-induced airway inflammation and mucus production in rats. Eur Respir J 2009;33:1122-1132.
19.
Guzeloglu M, Yalcinkaya F, Atmaca S, Bagriyanik A, Oktar S, Yuksel O, Fansa I, Hazan E: The beneficial effects of tadalafil on renal ischemia-reperfusion injury in rats. Urol Int 2011;86:197-203.
20.
Ustün H, Akgül KT, Ayyildiz A, Yağmurdur H, Nuhoğlu B, Karagüzel E, Oğüş E, Germiyanoğlu C: Effect of phospodiesterase-5 inhibitors on apoptosis and nitric oxide synthases in testis torsion: an experimental study. Pediatr Surg Int 2008;24:205-211.
21.
Erol B, Tokgoz H, Hanci V, Bektas S, Akduman B, Yencilek F, Mungan G, Mungan A: Vardenafil reduces testicular damage following ischemia/reperfusion injury in rats. Kaohsiung J Med Sci 2009;25:374-380.
22.
Beheshtian A, Salmasi AH, Payabvash S, Kiumehr S, Ghazinezami B, Rahimpour S, Tavangar SM, Dehpour AR: Protective effects of sildenafil administration on testicular torsion/detorsion damage in rats. World J Urol 2008;26:197-202.
23.
Yousefipour Z, Ranganna K, Newaz MA, Milton SG: Mechanism of acrolein-induced vascular toxicity. J Physiol Pharmacol 2005;56:337-353.
24.
Kovanecz I, Rambhatla A, Ferrini MG, Vernet D, Sanchez S, Rajfer J, Gonzalez-Cadavid N: Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection. BJU Int 2008;101:203-210.
25.
Phull H, Salkini M, Purves T, Funk J, Copeland D, Comiter CV: Angiotensin II plays a role in acute murine experimental autoimmune cystitis. BJU Int 2007;100:664-667.
26.
Arafa HM: Uroprotective effects of curcumin in cyclophosphamide-induced haemorrhagic cystitis paradigm. Basic Clin Pharmacol Toxicol 2009;104:393-399.
27.
Sakura M, Masuda H, Matsuoka Y, Yokoyama M, Kawakami S, Kihara K: Rolipram, a specific type-4 phosphodiesterase inhibitor, inhibits cyclophosphamide-induced haemorrhagic cystitis in rats. BJU Int 2009;103:264-269.
28.
Filippi S, Morelli A, Sandner P, Fibbi B, Mancina R, Marini M, Gacci M, Vignozzi L, Vannelli GB, Carini M, Forti G, Maggi M: Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007;148:1019-1029.
29.
Müller D, Mukhopadhyay AK, Davidoff MS, Middendorff R: Cyclic GMP signaling in rat urinary bladder, prostate, and epididymis: tissue-specific changes with aging and in response to Leydig cell depletion. Reproduction 2011;142:333-343.
30.
Hamsa TP, Kuttan G: Protective role of Ipomoea obscura (L.) on cyclophosphamide-induced uro- and nephrotoxicities by modulating antioxidant status and pro-inflammatory cytokine levels. Inflammopharmacology 2011;19:155-167.
31.
Korkmaz A, Topal T, Oter S: Pathophysiological aspects of cyclophosphamide- and ifosfamide-induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation. Cell Biol Toxicol 2007;23:303-312.
32.
Ilbey YO, Ozbek E, Simsek A, Otunctemur A, Cekmen M, Somay A: Potential chemoprotective effect of melatonin in cyclophosphamide- and cisplatin-induced testicular damage in rats. Fertil Steril 2009;92:1124-1132.
33.
Elangovan N, Chiou TJ, Tzeng WF, Chu ST: Cyclophosphamide treatment causes impairment of sperm and its fertilizing ability in mice. Toxicology 2006;222:60-70.
34.
Selvakumar E, Prahalathan C, Sudharsan PT, Varalakshmi P: Protective effect of lipoic acid on cyclophosphamide-induced testicular toxicity. Clin Chim Acta 2006;367:114-119.
35.
Tripathi DN, Jena GB: Astaxanthin inhibits cytotoxic and genotoxic effects of cyclophosphamide in mice germ cells. Toxicology 2008;248:96-103.
36.
Selvakumar E, Prahalathan C, Sudharsan PT, Varalakshmi P: Chemoprotective effect of lipoic acid against cyclophosphamide-induced changes in the rat sperm. Toxicology 2006;217:71-78.
37.
Higuchi H, Nakaoka M, Kawamura S, Kamita Y, Kohda A, Seki T: Application of computer-assisted sperm analysis system to elucidate lack of effects of cyclophosphamide on rat epididymal sperm motion. J Toxicol Sci 2001;26:75-83.
38.
Agarwal A, Saleh RA: Role of oxidants in male infertility: rationale, significance, and treatment. Urol Clin North Am 2002;29:817-827.
39.
Abbasi M, Alizadeh R, Abolhassani F, Amidi F, Hassanzadeh G, Ejtemaei Mehr S, Dehpour AR: Aminoguanidine improves epididymal sperm parameters in varicocelized rats. Urol Int 2011;86:302-306.
40.
Cai L, Hales BF, Robaire B: Induction of apoptosis in the germ cells of adult male rats after exposure to cyclophosphamide. Biol Reprod 1997;56:1490-1497.
41.
Koka S, Das A, Zhu SG, Durrant D, Xi L, Kukreja RC: Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect. J Pharmacol Exp Ther 2010;334:1023-1030.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.